Inhibition of Cytochrome P450 2C9 by essential oils by Cochrane, Meredith Lee & NC DOCKS at The University of North Carolina at Greensboro
 
 
 
COCHRANE, MEREDITH LEE, M.S. Inhibition of Cytochrome P450 2C9 by 
Essential Oils. (2015)  
Directed by Dr. Gregory M. Raner 61 pp. 
 
  
 Cytochrome P450 enzymes (CYP450) are the prominent member of a 
family of xenobiotic metabolizing enzymes that are collectively referred to as 
Phase 1 enzymes (1).   Phase 1 enzymes are responsible for taking reactive 
oxygen molecules and introducing them to inactive nonpolar substrates.  By doing 
this, the substrate becomes more polar which allows it to be easily excreted from 
the body (1).  They catalyze a monooxygenase reaction that involves a substrate 
(RH) that is oxidized by the addition of one oxygen from molecular oxygen (O2).  
These redox reactions can result in the production of reactive oxygen species 
which can cause oxidative stress in cells (1).   
 This study was designed to better understand the effect that essential oils 
had on the activity of Cytochrome P450 2C9.  The goal was to determine the 
potency of essential oils that caused the activity of CYP2C9 to drop to 50% or 
lower.  An initial screening process was done on all sixty essential oils to see 
which oils inhibited the activity of CYP2C9 by 50% or more.  The screening 
process found that there were seventeen oils that had the potential to be potent 
inhibitors of CYP2C9.  Those oils were: allspice, bergamot, cardamom, carrot 
seed, cinnamon leaf, citronella, clary sage, clove bud, elemi, eugenol, geranium 
bourbon, ginger, neroli, oregano vulgare, and vanilla absolute.   
 
 
 
The seventeen oils that decreased the activity of CYP2C9 to 50% or less 
were then analyzed using Michaelis-Menten kinetics to determine the Ki of the 
oils.  Of the seventeen oils tested, elemi had the lowest Ki values of 4.7 µg/mL 
and ginger had the highest Ki of 250 µg/mL.  The Michaelis-Menten kinetics also 
allowed for the type of inhibition to be classified as well.  Following the 
Michaelis-menten kinetics, reversibility studies and rate of inactivation studies 
were done on select essential oils to further classify the oils.
 
 
 
INHIBITION OF CYTOCHROME P450 2C9 BY ESSENTIAL OILS 
 
 
by 
 
Meredith Lee Cochrane 
 
 
A Thesis Submitted to  
the Faculty of the Graduate School at  
The University of North Carolina at Greensboro 
in Partial Fulfillment 
of the Requirements for the Degree 
Master of Science 
 
Greensboro 
2015 
     
       
        
       
    Approved by 
                                                                                        ___________________________ 
              Committee Chair
ii 
 
APPROVAL PAGE 
 
 
This thesis has been approved be the following committee of the Faculty of the 
Graduate School at the University of North Carolina at Greensboro. 
 
 
 
      Committee Chair   __________________________________ 
 Committee Members   _________________________________ 
                _________________________________ 
 
 
 
 
 
____________________________ 
Date of Acceptance by Committee 
 
_________________________ 
Date of Final Oral Examination
iii 
 
ACKNOWLEDGEMENTS 
 
 
First, I would like to thank Dr. Gregory Raner for his guidance, support and 
encouragement throughout my graduate career at UNCG.  I would also like to thank Dr. 
Jason Reddick for his support and guidance and support throughout my graduate career. 
Lastly, I would like to thank Dr. Alice Haddy for her support and guidance throughout 
my graduate career. 
  
iv 
 
TABLE OF CONTENTS 
 
Page 
  
LIST OF TABLES ...............................................................................................................v 
  
LIST OF FIGURES ........................................................................................................... vi  
 
CHAPTER  
 
 I. INTRODUCTION:  CYTOCHROME P450’S .....................................................1  
 
 I.A. Cytochrome P450 Enzyme. ..................................................................1  
 I.B. Inhibition of CYPP450 Enzymes. .........................................................8  
 I.C. Cytochrome P450 2C9. .......................................................................11 
 I.D. Cytochrome P450 2C9 Active Site. ....................................................12  
 I.E. Essential Oils. ......................................................................................14 
 
 II. MATERIALS AND METHODS .........................................................................16  
 
 II.A. Reagents: Chemicals Purchased. .......................................................16  
 II.B. Phosphate Buffer and NADPH Preparation. .....................................16 
 II.C. Human Liver Microsomes . ...............................................................17 
 II.D. Substrate Preparation.. .......................................................................17 
 II.E. CYP2C9 Inhibition Assay Conditions. ..............................................17  
 II.F. Initial Screening Assay for Inhibition  
                        of CYP2C9. ....................................................................................18 
 II.G. Michaelis-Menten Enzyme Kinetics Assay to 
                        Determine Ki for the Essential Oils. ..............................................18 
                        II.H. Two Stage Reversibility Studies for Binding to CYP2C9. ...............20 
 II.I. Rate of Inactivation Studies. ...............................................................23 
 II.J. HPLC Analysis. ..................................................................................25 
  
 III. RESULTS AND DISCUSSION ..........................................................................26 
 
III.A. Screening Assay Results. .................................................................26  
 III.B. Enzyme Kinetics Analysis. ..............................................................35 
 III.C. Reversibility Studies Results. ...........................................................56 
 III.D. Rate of Inactivation Studies .............................................................58 
  
BIBLIOGRAPHY ..............................................................................................................60
v 
 
LIST OF TABLES 
 
                Page 
Table 1.  Michaelis-Menten Enzyme Kinetics Assay ........................................................19  
 
Table 2.  Setup for the Preincubation Phase of the Reversibility Assay ............................20  
 
Table 3.  This Table Shows How the Incubation Phase Reaction was setup 
                    for the Reversibility Studies. ..........................................................................22 
 
Table 4.  This Table Shows How the Preincubation Phase (Stage 1) was setup for 
                    the Rate of Inactivation Reaction. ..................................................................23 
 
Table 5.  This Table Shows How the Incubation Phase Reactions were setup 
                    for the Rate of Inactivation Reaction. ............................................................24 
 
Table 6.  This Table Lists all the Essential Oils Tested and Their Respective 
                    Concentrations in each Reaction. ...................................................................29 
 
Table 7.  This Shows the Michaelis-Menten Calculations for the Seventeen Oils  
                    that Showed >50% Inhibition of CYP2C9 Activity ......................................36  
 
Table 8.  Results of Reversibility Studies.. ........................................................................57  
 
  
vi 
 
LIST OF FIGURES 
 
    Page 
Figure 1.  Cytochrome P450 Heme Iron III Center. ............................................................2  
 
Figure 2. Oxidation and Reduction of the Iron Center of the Hemeprotein ........................4  
 
Figure 3.  Difference between Low Spin and High Spin States. .........................................5  
 
Figure 4.  Interaction of the Ferryl Iron Center with the Nonpolar Substrate via a 
                    Radical Mechanism in which there is a Hydrogen Abstraction and 
                    Oxygen Rebound Reaction to form the Hydroxylated Product…. ..................6  
 
Figure 5. The Two Different Metabolic Pathways that can Occur in the CYP450’s 
                    Catalytic Cycle. ................................................................................................7  
 
Figure 6.  This Shows the Michaelis-Menten Model of Enzyme Kinetics for 
                     Competitive Inhibition. .................................................................................11  
 
Figure 7. This Figure Shows the Metabolism of Diclofenac to 4-Hydroxydiclofenac 
                    by CYP2C9 ....................................................................................................12  
 
Figure 8. (S)-warfarin and Fluribprofen Bound in Crystal Structures. ..............................13 
 
Figure 9. This Figure Depicts the Process by which Essential Oils are Produced 
                    via Steam Distillation  . ..................................................................................14 
 
Figure 10 Chromatogram Showing the Separation when using the Modified 
                     Mobile Phase... ..............................................................................................28 
 
Figure 11a. This Figure Shows the Essential Oils that Exhibited ≤20% Inhibition 
                        of CYP2C9 Activity... ................................................................................30 
 
Figure 11b. This Figure Shows the Essential Oils that Exhibited ≤30% Inhibition 
                        of CYP2C9 Ictivity. ...................................................................................31 
 
Figure 11c. This Figure Shows the Essential Oils that Exhibited ≤40% Inhibition  
                        of CYP2C9 Activity ...................................................................................32 
 
 
 
 
vii 
 
Figure 11d. This Figure Shows the Essential Oils that Exhibited <50% Inhibition  
                        of CYP2C9 Activity ...................................................................................33 
 
Figure 12. This Graph Shows the Seventeen Essential Oils that Showed >50%  
                      Inhibition of CYP2C9 Activity when Compared to an Uninhibited  
                      Reaction .......................................................................................................34 
 
Figure 13. Plot Area vs. Diclofenac (µM) Concentration in the Presence 
                     (blue circles) and Absence (red triangles) of Elemi ......................................38 
 
Figure 14. Plot Area vs. Diclofenac (µM) Concentration in the Presence 
                     (blue circles) and Absence (red triangles) of Ginger Oil ..............................39 
 
Figure 15. Plot Area vs. Diclofenac (µM) Concentration in the Presence  
                     (blue circles) and Absence (red triangles) of  
                     Geranium Bourbon oil. .................................................................................41 
 
Figure 16. Plot Area vs. Diclofenac (µM) Concentration in the Presence  
                     (blue circles) and Absence (red triangles) of Coriander Oil .........................42 
 
Figure 17. Plot Area vs. Diclofenac (µM) Concentration in the Presence  
                     (blue circles) and Absence (red triangles) of Cinnamon Leaf Oil ................43 
 
Figure 18. Plot Area vs. Diclofenac (µM) Concentration in the Presence   
                     (blue circles) and Absence (red triangles) of Clove bud Oil. .......................44 
 
Figure 19. Plot Area vs. Diclofenac (µM) Concentration in the Presence   
                     (blue circles) and Absence (red triangles) of Eugenol Oil ............................45 
 
Figure 20. Plot Area vs. Diclofenac (µM) Concentration in the Presence  
                     (blue circles) and Absence (red triangles) of Citronella Oil .........................46 
 
Figure 21. Plot Area vs. Diclofenac (µM) Concentration in the Presence  
                     (blue circles) and Absence (red triangles) of Oregano Vulgare Oil .............47 
 
Figure 22. Plot Area vs. Diclofenac (µM) Concentration in the Presence  
                     (blue circles) and Absence (red triangles) of Carrot Seed Oil ......................48 
 
Figure 23. Plot Area vs. Diclofenac (µM) Concentration in the Presence  
                     (blue circles) and Absence (red triangles) of Bergamot Oil .........................49 
 
 
 
viii 
 
Figure 24. Plot Area vs. Diclofenac (µM) Concentration in the Presence  
                     (blue circles) and Absence (red triangles) of Clary Sage Oil .......................50 
 
Figure 25. Plot Area vs. Diclofenac (µM) Concentration in the Presence  
                     (blue circles) and Absence (red triangles) of Neroli Oil ...............................51 
 
Figure 26. Plot Area vs. Diclofenac (µM) Concentration in the Presence  
                     (blue circles) and Absence (red triangles) of Petitgrain Oil .........................52 
 
Figure 27. Plot Area vs. Diclofenac (µM) Concentration in the Presence  
                     (blue circles) and Absence (red triangles) of Vanilla Oil .............................53 
 
Figure 28. Plot Area vs. Diclofenac (µM) Concentration in the Presence  
                     (blue circles) and Absence (red triangles) of Cardamom Oil .......................54 
 
Figure 29. Plot Area vs. Diclofenac (µM) Concentration in the Presence  
                     (blue circles) and Absence (red triangles) of All Spice Oil ..........................55 
 
Figure 30. Rate of Inactivation Assay Plot for Oregano Vulgare. .....................................59 
1 
 
CHAPTER I 
 
INTRODUCTION:  CYTOCHROME P450’S 
 
 
I.A. Cytochrome P450 Enzyme 
Cytochrome P450’s (CYP P450) are the prominent member of a family of 
xenobiotic metabolizing enzymes, collectively referred to as Phase 1 enzymes.  Phase 1 
enzymes are responsible for chemically transforming foreign species into more polar 
products that may be easily removed from the body (1).  These reactions can occur by 
reduction, oxidation, cyclization, or decyclization.  A problem that can be encountered by 
this metabolism is that cytochrome P450’s convert inert xenobiotics and turn them into 
reactive compounds that in some cases are poisonous to the human body.  Cytochrome 
P450’s catalyze a monooxygenase reaction that involves a nonpolar substrate that is 
oxidized by the addition of one oxygen atom from molecular oxygen.  In addition to 
reactive metabolites, these redox reactions can result in the production of reactive oxygen 
species which can lead to oxidative stress in cells (1).  Reactive oxygen species include 
hydrogen peroxide, superoxide, hydroxyl radicals, and other related chemical species.   
CYP 450’s are part of a broader protein family called the heme proteins which are 
so-named because they use a heme prosthetic group to carry out oxidative chemistry (2).   
Figure 1 depicts what the heme center looks like.  In the center of the hemeprotein there
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is an iron atom that plays a key role in catalysis.  The figure shows that the iron is in the 
center and bound to four surrounding nitrogens that are part of pyrrole rings.  The iron 
center is also covalently bound to a cysteine ligand in the active site.  In the resting state, 
there is also a water molecule bound to the iron center. 
 
Figure 1.  Cytochrome P450 Heme Iron III Center.  This shows the covalent bond 
between the iron III center and the sulfur of the cysteine ligand.  The four pyrole rings are 
shown, labeled A-D, as well as the four nitrogen ligands that surround the iron III canter 
(2). 
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Before the substrate can be hydroxylated the iron center needs to be prepared.  
Figure 2 shows the process of preparing the iron center.  When cytochrome P450’s are in 
the resting state, which has water present in the active site and all six ligands bound, the 
ferric iron center is in a low spin state.  In this low spin state there is one unpaired 
electron.  Once the substrate enters the active site, the water molecule is displaced which 
causes a change from a low spin state to a high spin state (4).  When the iron center is 
shifted from a low spin state to a high spin state there is a splitting of d orbitals that 
occurs which results in three unpaired electrons as shown in Figure 3. After the substrate 
enters the active site and causes the ferric iron center to shift from a low spin state into a 
high spin state.  This change in electronic state also causes a conformation change in the 
enzyme active site which causes the transfer of an electron from NADPH to a 
flavoprotein more favorable.  
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Figure 2.  Oxidation and Reduction of the Iron Center of the Hemeprotein.  This shows 
the progression of the preparation of the heme center in order for it to be able to interact 
with the substrate. 
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Figure 3.  Difference between Low Spin and High Spin States.  This shows what the spin 
state looks like when water is covalently bound to the heme center (low spin state) and 
when the water is displaced upon the substrate binding in the active site (high spin state). 
 
 
 
 
 
 
 
  
 
Once in this high spin state, the ferric center can be reduced to a ferrous center by 
a single electron transfer reaction from a flavoprotein, which got the electron donated 
from NADPH.  Once the ferric center is reduced to the ferrous center, molecular oxygen 
can bind to the ferrous center through a radical reaction, shown in Figure 2.  Due to the 
proximity of the Cys ligand, molecular oxygen is more reactive than normal.  Once 
molecular oxygen is bound, the ferrous iron is oxidized back to a ferric iron center (5).  
The next step in the preparation of the iron center is dealing with the radical charge on 
oxygen.  A single electron transfer occurs between another flavoprotein, which got its 
electron from the same molecule of NADPH, and the radical oxygen.  Then the 
negatively charged oxygen is reduced into a peroxo group.  Next the peroxo group is 
either protonated twice by a water molecule present in the active site or one of the amino 
acid side chains surrounding it and oxidizes the iron center into a ferryl heme center.  In 
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this ferryl state, the heme center can now interact with the nonpolar substrate.  Once the 
ferryl heme center is present it immediately reacts with the nonpolar substrate via a 
radical mechanism, as shown in Figure 4 (6). 
 
Figure 4.  Interaction of the Ferryl Iron Center with the Nonpolar Substrate via a Radical 
Mechanism in which there is a Hydrogen Abstraction and Oxygen Rebound Reaction to 
form the Hydroxylated Product. 
 
 
In step 1 the nonpolar substrate interacts with the ferryl heme center.  In this 
reaction the single bond between the hydrogen and the rest of the nonpolar substrate 
splits, with one electron going to the adjacent carbon and the other forming a bond with 
the oxygen attached to the ferryl center.  In order for the OH bond to be formed an 
electron has to be donated back to the heme center causing a reduction in the heme 
center.  In step 2, the radical substrate is now going to interact with the OH group 
attached to the heme center by another radical mechanism.  When the bond between the 
heme center and the OH group is broken, a new bond is formed between the substrate and 
the OH group and the heme center is again reduced to a ferric state (6).  After the 
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hydroxylation of the substrate, a free water in the active site will covalently bond to the 
heme center and return the cytochrome P450 active site to its resting state. 
All of the events described above refer to the productive pathway of cytochrome 
P450’s, shown in Figure 4. In some instances there is a chance for an uncoupling reaction 
to happen, which results in the production of hydrogen peroxide.  This path way is known 
as the unproductive pathway, shown in Figure 5 (7). 
 
Figure 5.   The Two Different Metabolic Pathways that can Occur in the CYP450’s 
Catalytic Cycle.  Top:  the productive pathway which shows progression from the peroxo 
heme center to the hydroxylated product. Bottom:  the nonproductive pathway which 
shows the progression from the peroxo heme center to the release of hydrogen peroxide 
and the CYP450 back in its resting state. 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
Hydroxide Radicals 
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This uncoupling pathway occurs when the oxygen attached to the ferric iron 
center is protonated instead of water being released from the iron center.  When the 
oxygen directly connected to the iron center is protonated it causes the release of 
hydrogen peroxide.  In order to return to the resting state a water molecule will come and 
bind to the heme center.  Once hydrogen peroxide is released it can be degraded into to 
hydroxide radicals which causes oxidative stress.  In some instances, this uncoupling 
reaction can occur when the substrate is interacting with the ferryl heme center in which 
the electron transfer is not coordinated correctly in the catalytic cycle (8). 
Cytochrome P450’s are responsible for metabolism of many xenobiotics that enter 
the body.  However, this family of enzymes are also involved in the activation of inactive 
compounds that can potentially be toxic to the liver.  An example of this is when 
acetaminophen is bioactivated into a reactive, N-acetyl-p-benzoquinonimine (NADPQI). 
NADPQI is a reactive metabolite that can bind to DNA, RNA, and proteins which leads 
to cellular necrosis (8). 
 
I.B.  Inhibition of CYP450 Enzymes 
 As stated previously, cytochrome P450 enzymes are responsible for detoxifying 
the body of xenobiotics, which includes the metabolism of pharmaceutical compounds 
(9).  Like other enzymes present in the human body, the activity of CYP450 enzymes 
toward a specific substrate can be altered by the presence of a competing compound or 
related substrate.  The focus of this study is on cytochrome P450 inhibition by nonpolar 
organic compounds found in various essential oils (9). 
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 An inhibitor is any molecule that blocks the enzymatic metabolism of the desired 
substrate, which leads to a decrease in the overall CYP450 enzymatic activity.  When the 
metabolism of a drug by CYP450 is inhibited it can lead to an increase in the drug’s 
availability in the body and thus increasing the probability for adverse drug effects.  How 
the inhibitor binds to the active site determines the type of inhibition that is occurring, 
which can fall in two categories:  irreversible and reversible (9). 
 A reversible inhibitor binds to the CYP450 active site prior to the substrate being 
oxidized.  The effects of a reversible inhibitor only last as long as the inhibitor is present 
in the active site (10).  The way that a reversible inhibitor binds to the active site is 
usually through either lipophilic attractions to the amino acid side chains present in the 
active site or through hydrogen bonding.  For example, imidazole derivatives typically 
have a tight binding affinity due to their higher nucleophilicity and thus have a higher 
attraction to the heme iron center when compared to the substrate.  Alcohols and ketones 
tend to have weaker binding affinities for binding to the heme iron center and are 
classified as weak irreversible inhibitors (10). 
 Irreversible inhibitors often bind covalently to the enzyme.  By binding covalently 
to the active site, the inhibitor chemically alters the enzyme structure which permeantly 
deactivates the enzyme.  When the inhibitor is activated by the enzyme prior to 
inactivation, these inhibitors are referred to as “suicide inhibitors”.  Irreversible inhibitors 
of P450 enzymes usually involve chemical modification of the heme cofactor (11). 
10 
 
 The Michaelis-Menten model is universally used to determine enzyme activities 
of CYP450 enzymes.  As seen in Figure 6, the Michaelis-Menten model demonstrates the 
relationship between activity and the substrate concentration.  The Vmax represents the 
maximum rate of product formed after the saturation of all available enzymes by the 
substrate.  The other variable that is able to be determined by this model is Km, which 
represents the substrate concentration at Vmax.  The Km shows where 50% of the substrate 
is bound to the enzyme.  When an inhibitor is introduced to this model, it can be used to 
describe the nature of the interaction between CYP 450 enzymes and the molecules that 
inhibit the enzyme.  There are several types of inhibition for CYP450 enzymes that can 
be shown by Michaelis-Menten kinetics: competitive inhibition, uncompetitive, and 
noncompetitive inhibition.  Competitive inhibition is where the substrate and the inhibitor 
are competing for the same active site. When one binds it will block the other and vice 
versa (12). In noncompetitive inhibition, the inhibitor reduces the activity of the enzyme 
and will bind equally to the enzyme if it has bound substrate or not (12).  Uncompetitive 
is the most common form and occurs when inhibitors bind only when the substrate is 
bound to the active site first. 
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Figure 6.  This Shows the Michaelis-Menten Model of Enzyme Kinetics for Competitive 
Inhibition.  This illustration shows the nonlinear relationship between reaction rate V and 
substrate concentration [S], along with the corresponding Vmax and Km constants. 
 
 
I.C.  Cytochrome P450 2C9 
Cytochrome P450 2C9 (CYP2C9) plays a key role in metabolizing xenobiotics 
and endogenous compounds.  CYP2C9 constitutes approximately 18% of the cytochrome 
P450 enzymes found in the human liver.  It has also been found that CYP2C9 is the 
second most common cytochrome P450 in the small intestine.  Some of the drugs that are 
metabolized by CYP2C9 are ibuprofen, naproxen, warfarin, and hypoglycemic agents 
such as tolbutamide.  Along with the other pharmaceuticals mentioned, CYP2C9 is also 
know to metabolize diclofenac.  Diclofenac is a nonsteroidal anti-inflammatory drug that 
is typically prescribed for relieving moderate pain (13).  After metabolism approximately 
 
12 
 
65% of the hydroxylated product is excreted in the urine after undergoing enterohepatic 
circulation (13).  In the case of CYP2C9, diclofenac enters the active site of the enzyme 
and is hydroxylated in the four position, creating 4-hydroxydiclofenac.  Figure 7 shows 
the reaction of diclofenac metabolism. 
 
Figure 7.  This Figure Shows the Metabolism of Diclofenac to 4-Hydroxydiclofenac by 
CYP2C9. 
 
 
 
I.D.  Cytochrome P450 2C9 Active Site 
As mentioned before CYP2C9 is the second most prominent form of hepatic P450 
and it has a preference for metabolizing weakly acidic substrates (14).  Studies have been 
done in order to determine how substrates are arranged in the active site with relation to 
the heme center of the CYP450.  In a study conducted by Mosher, the cytochrome P450 
active site was mutated to see the relative effect on metabolism of warfarin and 
fluribprofen.    The active site of most cytochrome P450’s is very hydrophobic containing 
phenylalanine residues.  In the study conducted by Mosher, site directed mutagenesis of 
CYP2C9 
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three key phenylalanine residues, F100, F114, and F476 was used to determine the 
functionality of the phenylalanine residues.  This was done by single and double 
mutations of the three key residues previously mentioned to either lysine or tryptophan.  
Figure 8 shows the crystals structures of warfarin and fluribprofen bound to the CYP2C9 
active site (wild type).  It appears that the orientation of the substrate in the active site of 
CYP450 is related to the phenylalanine arrangement.  The arrangement of the 
phenylalanine residues determined the distance that the substrate was in relation to the 
heme center, which is key for catalysis (14). 
 
Figure 8.  (S)-warfarin and Fluribprofen Bound in Crystal Structures.  In panel A, the 
crystal structure for warfarin (1OG5) bound to the CYP2C9 active site.  In Panel B, the 
crystal structure for fluribprofen bound to the CYP2C9 active site.  The view is looking 
down the access channel to the heme center (red).  The distances from the sites of 
oxidation to the heme iron are shown by dotted lines (14). 
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I.E.  Essential Oils 
Essential oils are plant derived oils used in the flavoring of foods and the 
cosmetics industries, in addition to their wide spread usage in natural therapies and 
supplements to treat or prevent a host of health conditions.  Essential oils can be extracted 
by using one of seven methods: enfleurage, expressed oils, steam distillation, solvent 
extraction, fractional distillation and percolation, carbon dioxide extraction, and phytonic 
process (15).  The most commonly used method is steam distillation.   Figure 9 shows the 
process by which steam distillation is used to produce essential oils.   
 
Figure 9.  This Figure Depicts the Process by which Essential Oils are Produced via 
Steam Distillation. 
 
 
First, the plant materials and water are mixed together. Then in a separate 
container, water is heated to produce steam which is shuttled into the container with the 
water and plant materials.  The steam will eventually vaporize the water and the nonpolar 
organic molecules present in the plant materials.  Once the nonpolar molecules and water 
are vaporized, they are sent through a series of condensing coils which facilitates the 
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formation of floral water and the essential oils.  After condensing the mixture, they are 
transferred into a storage container which allows for the separation of the floral water and 
the essential oil.  The essential oil mixture will be on top of the floral water since it is less 
dense.  The essential oil mixture will be comprised mostly of volatile nonpolar 
compounds (15).   
Essential oils have a wide variety of uses ranging from food flavoring to 
therapeutic treatments which allows for there to be many ways for them to be introduced 
into the body.  There are four ways in which essential oils can be introduced into the 
body, inhalation, absorbing the oils the skin, absorbing the oils through orifices on the 
body, and through direct consumption of the oils (15).   There are a variety of opinions on 
which way is best to administer the essential oils.  Because essential oils are composed of 
a large number of mostly nonpolar molecules, they have the potential to act as inhibitors 
of human cytochrome P450’s.  The most common route for this to occur is via reversible 
binding of the inhibitor to the active site of the enzyme, taking the place of the substrate 
and thus competing for the active site (10).  Depending on whether the P450 enzyme is 
taking part in a productive or nonproductive metabolic process, this inhibition could have 
a positive or negative health consequences.  The broad goal of this study is to identify 
possible interactions between a large number of essential oils and the human CYP2C9.
16 
 
CHAPTER II 
 
MATERIALS AND METHODS 
 
 
II.A. Reagents: Chemicals Purchased 
The chemicals used during these experiments were purchased from different 
companies.  The human liver microsomes were purchased from Xenotech.  The 
diclofenac was purchased from Sigma.  The p-Cymene was purchased from Aldrich. The 
limonene and eugenol (99%) were purchased from Acros Chemicals.  All other essential 
oils were purchased from Birch Hill Happenings Aromatherapy.  The monobasic and 
dibasic potassium phosphate were purchased from Carolina Biological Supply Company.  
The acetonitrile used for the mobile phase was purchased from Fischer.  The NADPH 
was purchased from Research Products International. 
II.B. Phosphate Buffer and NADPH Preparation 
 Potassium phosphate buffer was prepared by mixing monobasic potassium 
phosphate and dibasic potassium phosphate.  A 1 M stock solution at pH 7.4 was used for 
all assays involved in this project.  The NADPH was diluted with Nano-pure water and 
partitioned into 10 mM stock solution aliquots.  The aliquots were stored in a freezer at -
80oC.
17 
 
II.C. Human Liver Microsomes 
 Human liver microsomes were purchased from Molecular Toxcology Inc. They 
were put in 75 µL aliquots and stored in a freezer at -800C for usage. 
II.D. Substrate Preparation 
 The reagent diclofenac was purchased from Sigma-Aldrich. 33.78 mg of 
diclofenac was weighed out and dissolved in 10 mL of deionized water to give 10 mM 
stock solution. This solution was then diluted 1:10, to give a final concentration of 1 mM 
stock solution of diclofenac, which was used as a substrate for all assays that involved 
CYP2C9 enzyme. 
II.E. CYP2C9 Inhibition Assay Conditions 
Enzyme kinetics studies were used to study the effects of essential oils on the 
activity of CYP2C9.  The essential oils tested were:  all spice, anise, bergamot, birch, 
camphor, cardamom, carrot seed, cedarwood, cinnamon leaf, citronella, clary sage, clove 
bud, p-Cymene, cypress, dill seed, douglas fir, elemi, eucalyptus lemon, eugenol, fennel, 
frankincense, geranium bourbon, ginger, grapefruit, hyssop, jasmine absolute, juniper 
berry, lavender, lemongrass, lime, mandarin, marjoram, Melissa pure, myrtle, myrrh, 
neroli, nutmeg, oregano vulgare, patchouli, pennyroyal, pepper (black), peppermint, 
petitgrain, pine needle, ravensara, roman chamomila, rose absolute, rosemary, rosemary 
verbenon, rosewood, sage, sandalwood, spearmint, spruce needle, tangerine, thyme 
borneal, vanilla absolute, wintergreen, and ylang ylang. 
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II.F. Initial Screening Assay for Inhibition of CYP2C9 
The assay was used to measure the amount of inhibition of CYP2C9 in oxidizing 
diclofenac to 4-hydroxydiclofenac.  The essential oil solutions were made by taking 1 µL 
of the oil being tested and dissolving it in 10 µL of deionized water.  Conditions for the 
screening consisted of 8 µL of microsomes being incubated with 61 µL of deionized 
water, 100 mM phosphate buffer (7.4 pH), 50 µM of the substrate diclofenac (1mM stock 
solution), 1.0 mM NADPH, and 100 µL of the diluted essential oil being tested (actual 
concentrations reported based on density).   Once all the components were mixed in a 
microcentrifuge tube, the reaction was incubated for 30 minutes at 37 oC. At the end of 
incubation, the reaction was quenched with 94%acetonitrile/6% glacial acetic acid 
solution and placed on ice for ten minutes to ensure that the reaction was stopped.  Then 
the tubes were centrifuged at 13,000 rpm for 10 minutes.  After centrifugation, 200 µL of 
the supernatant was placed in miniprep HPLC vials and analyzed by HPLC. 
II.G. Michaelis-Menten Enzyme Kinetics Assay to Determine Ki for the Essential 
Oils 
The Michaelis-Menten model of enzyme kinetics was used to determine the KI for 
each oil, expressed as µg oil/ mL.  Table 1 shows how the reactions were set up for each 
Michaelis-Menten study. 
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Table 1.  Michaelis-Menten Enzyme Kinetics Assay.  Reaction set up for the Michaelis-
Menten enzyme kinetics. 
Concentration of 
Substrate 
DI water Buffer 
(pH 7.4) 
Microsome NADPH    Inhibitor  
0 μM 52 µL 100 mM 8 µL 1 mM 100 µL 
25 μM   47 µL 100 mM 8 µL 1 mM 100 µL 
55 μM   41 µL 100 mM 8 µL 1 mM 100 µL 
125 μM      2 µL 100 mM 8 µL 1 mM 100 µL 
 
 
The Ki values were found by plotting the relative activity (v) vs. the substrate 
concentration ([S]) at a range of increasing diclofenac concentration (0 μM to 125 μM) in 
the presence and absence of inhibitor.  The concentration of the inhibitor was chosen 
based on the results of the screening experiments that gave >50% inhibition of CYP2C9.  
The Slide Write Plus program, by Advanced Graphics Software, Inc., was used to plot the 
relative activities vs. the concentration of diclofenac.  The Michaelis-Menten equation 
(Equation 1) was used to determine the Vmax, Vmax app, Km, and Km app.  The oils that 
showed >50% inhibition showed competitive inhibition and Equation 2 was used to solve 
for the Ki. 
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Equation 1.  The Michaelis-Menten Equation. 
 
 
Equation 2.  This equation was used to calculate the Ki by using the concentration of 
inhibitor used in the reaction 
Km app/Km = 1+ [I]/Ki 
 
 
II.H. Two Stage Reversibility Studies for Binding to CYP2C9 
 Preliminary studies showed that there was definite inhibition of CYP2C9 in the 
presence of seventeen essential oils, the next phase was to look at how the enzyme was 
inhibited.  A two phase method was used to determine if the inhibition present was 
reversible or irreversible.  Table shows the parameters for the preincubation phase (stage 
1).  After the vials shown in Table are set up, they are preincubated at 37oC for ten 
minutes.  
 
Table 2. Setup for the Preincubation Phase of the Reversibility Assay. 
 
Vial 1 Vial 2 Vial 3 
Microsomes 20 µL Microsomes 20 µL Microsomes 20 µL 
Buffer 100 mM Buffer 100 mM Buffer 100mM 
Inhibitor 40 µL Inhibitor 40 µL  Inhibitor 40 µL 
DI Water 20 µL DI Water 40 µL DI Water 70 µL 
NADPH 1 mM   
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 After a ten minute preincubation, 40 µL from the stage 1 vials was transferred to 
the stage 2 vials of the experiment.  In stage 2, the vials had 40 µL from each respective 
vial from stage 1, 11 µL of diclofenac, 20 µL of potassium phosphate buffer, 20 µL of 
NADPH, and 109 µL of deionized water, as shown in Table 3.  Vial 1 in this experiment 
represented reaction conditions which would allow the inhibitors present in the essential 
oils to do damage to the cytochrome P450, if the reaction is irreversible then there would 
be no or a decreased amount of remaining activity toward the substrate when the 40 µL is 
transferred to stage 2, but if it happens to be reversible then there would be a fully 
activity with the substrate in stage 2 to the cytochrome P450.  NADPH is added to vial 1 
to see if the inhibition of the cytochrome P450 is dependent on NADPH.  In vial 2, 
everything is the same as in vial 1, except that no NADPH is present.  Vial 3 represents a 
control, with microsomes and buffer, when transferred to stage 2 the substrate should be 
able to bind to the cytochrome P450 and give full activity which can be compared to vial 
1 and vial 2. 
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 Table 3.   This Table Shows How the Incubation Phase Reactions were setup for the 
Reversibility Studies.  The stock solution consists of 1mM of NADPH, 100 mM of 
potassium phosphate buffer, 55 µM of diclofenac, and deionized water.  The sock 
solution is made by taking the respective volumes mentioned and multiplying them by 
the number of vials for stage 2 of the reaction. 
Vial 1a Vial 1b Vial 2a Vial 2b Vial 3a Vial 3b 
40 µL of 
preincub-
ation 
solution 1 
40 µL of 
preincub-
ation 
solution 1 
40 µL of 
preincub-
ation solution 
2 
40 µL of 
preincub-
ation 
solution 2 
40 µL of 
preincub-
ation 
solution 3 
40 µL of 
preincub-
ation  
solution 3 
160 µL of 
the stock 
solution 
160 µL of 
the stock 
solution 
160 µL of 
the stock 
solution 
160 µL of 
the stock 
solution 
160 µL of 
the stock 
solution 
160 µL of 
the stock 
solution 
 
 
 After the transfer of 40 µL of the preincubation reactions from stage 1 into the 
stage 2 vials, the reactions are incubated at 37oC for ten minutes.  After the ten minute 
incubation period, the reactions were quenched with 94% acetonitrile/6% glacial acetic 
acid solution.  The quenched reactions were then put on ice for ten minutes to allow for 
any excess proteins and particulates to precipitate out of solution.  Then the tubes were 
centrifuged at 13,000 rpm for 8 minutes.  Then 200 µL of the supernatant was taken and 
analyzed by HPLC. 
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II.I. Rate of Inactivation Studies 
 Rate of inactivation studies were done to determine the rate at which the 
inhibitors present in the essential oils was deactivating the cytochrome P450 enzyme.  
Like the reversibility studies, there are two phases in which the reaction occurs:  the 
preincubation phase (stage 1) and the incubation phase (stage 2).  In stage 1 there are 2 
vials, as shown is Table 4. 
 
Table 4.  This Table Shows How the Preincubation Phase (Stage 1) was setup for the 
Rate of Inactivation Reaction.  Vial 1 contains NAPDH, inhibitor, microsomes, buffer, 
and water.  Vial 2 contains buffer, deionized water, and microsomes. 
Vial 1 Vial 2 
Microsomes 80 µL Microsomes 80 µL 
Buffer 100 mM Buffer 100 mM 
Deionized water  Deionized water  
NADPH 40 1 mM  
Inhibitor (varied based on 
inhibitor) 
 
 
  
The total reaction volume for the preincubation phase of the reaction.  The vials in 
stage 1 were incubated for a total time of thirty minutes.  At ten, twenty, and thirty 
minutes of the preincubation phase, 40 µL of the reaction was removed from the vial and 
placed in a vial for stage 2 (incubation phase).  Table 5 shows the setup for the incubation 
phase of the rate of inactivation study.  Once 40 µL of stage 1 were removed at the 
appropriate preincubation times and added to stage 2, the vials for stage 2 received 160 
µL of stock solution added to them to bring the total reaction volume for the incubation 
phase to 200 µL.  The stock solution consists of 20 µL of NADPH, 20 µL of potassium 
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phosphate buffer, 11 µL of diclofenac, and 109 µL of deionized water.  The sock solution 
was made by taking the respective volumes mentioned and multiplying them by the 
number of vials for the incubation phase of the reaction.  The vials were then incubated at 
37oC for thirty minutes.  After the thirty minute incubation, the reactions were quenched 
with a 94% acetonitrile/ 6% glacial acetic acid solution and placed on ice for eight 
minutes.  Then the vials were centrifuged at 13,000 rpm for 10 minutes.  Then 200 µL of 
the supernatant was taken for HPLC analysis. 
 
Table 5.   This Table Shows How the Incubation Phase Reactions were setup for the Rate 
of Inactivation Studies.  The stock solution consists of 1mM of NADPH, 100 mM of 
potassium phosphate buffer, 55 µM of diclofenac, and deionized water.  The sock 
solution is made by taking the respective volumes mentioned and multiplying them by 
the number of vials for the incubation stage of the reaction. 
 
Vial 1a Vial 1b Vial 2a Vial 2b Vial 3a Vial 3b 
40 µL of 
preincub- 
ation 
solution 1 
40 µL of 
preincub- 
ation 
solution 1 
40 µL of 
preincub-
ation 
solution 2 
40 µL of 
preincub-
ation 
solution 2 
40 µL of 
preincub-
ation 
solution 3 
40 µL of 
preincub-
ation 
solution 3 
160 µL of 
the stock 
solution 
160 µL of 
the stock 
solution 
160 µL of 
the stock 
solution 
160 µL of 
the stock 
solution 
160 µL of 
the stock 
solution 
160 µL of 
the stock 
solution 
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II.J. HPLC Analysis 
 The reaction monitored in this study was the hydroxylation of diclofenac to 4-
hydroxydiclofenac.  This oxidation was monitored by HPLC (high-performance liquid 
chromatography).  The analysis was conducted using a Shimadzu Automated liquid 
Chromatography system with UV detection set at 220 nm.  The system was programed to 
inject 50 µL of each sample onto a C18 column (4.6x150 mm) with a flow rate of 1.0 
mL/min.  The mobile phase used for this method contained 20 mM phosphoric acid in a 
50% acetonitrile/ 50% deionized water.  The 4-hydroxydiclofenac peak for each reaction 
was integrated to give peak areas, where the area under the curve represents the relative 
activity of the CYP2C9 enzyme found in the human liver microsomes.
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CHAPTER III 
 
 RESULTS AND DISCUSSION 
 
 
III.A. Screening Assay Results 
 There were problems encountered in the initial screening of inhibitory activity 
caused by essential oils on CYP2C9 activity.  Some oils contained constituents that has 
the same retention time as 4-hydroxydiclofenac.  The original HPLC analysis used a 
mobile phase containing 50%acetonitrile/ 50% water with 0.1% trifluoracetic acid.  
While this mobile phase allowed for effective separation of the constituents, most of the 
essential oils had some constituents that had the same retention time as 4-
hydroxydiclofenac.  In order to increase the retention time of these essential oil 
constituents, the mobile phase was changed to be more acidic which would promote a 
longer retention time of the nonpolar molecules of the essential oils. Modifying the 
mobile phase allowed for better separation of the essential oil constituents and the 
product 4-hydroxydiclofenac. Figure 10 shows a chromatogram where the modified 
mobile phase was used.  There is a distinct separation between the product 4-
hydroxydiclofenac (shown at approximately 3.5 minutes) and the essential oil 
constituents of all spice oil (shown approximately 4.2 minutes).
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The interaction of CYP2C9 with a wide range of essential oils led to the inhibition of this 
enzyme.  This was shown by using an enzymatic assay in which the oxidation of 
diclofenac to 4'-hydroxydiclofenac was measured by HPLC analysis.  The screening used 
to measure inhibition was successful in finding potent inhibitors which showed an 
inhibition of 50% or more when compared to a standard reaction.  The essential oil 
solutions were prepared by taking 1 µL of oil and diluting it in 10 mL of DI water.  Based 
on the measured density of each oil, this gave concentrations of the stock solutions 
ranging from 26 µg/mL to 88 µg/mL.  In each inhibition reaction, 100 µL of the essential 
oil solutions were included in a 200 µL total reaction volume.  Table 6 lists all of the 
essential oils and the amounts present in each inhibition reaction.  Figures 11a, 11b, 11c, 
and 11d shows all the essential oils tested and their relative activity compared to an 
uninhibited reaction.  
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Figure 10. Chromatogram Showing the Separation when using the Modified Mobile 
Phase.  An uninhibited reaction is shown in red and a reaction inhibited by all spice is 
shown in blue.  
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Table 6.  This Table Lists all the Essential Oils tested and Their Respective 
Concentrations in each Reaction.  
Essential Oil Reaction 
Concentration 
(µg/mL) 
Essential Oil Reaction 
Concentration 
(µg/mL) 
All Spice 51 Lime 88 
Anise 61 Mandarin 42 
Bergamot 37 Marjoram 50 
Birch 66 Melissa Pure 63 
Camphor 47 Myrtle 48 
Cardamom 40 Myrrh 74 
Carrot Seed 36 Neroli 39 
Cedarwood 29 Nutmeg 46 
Cinnamon Leaf 51 Oregano Vulgare 40 
Citronella 42 Patchouli 36 
Clary Sage 35 Pennyroyal 49 
Clove Bud 45 Pepper (black) 33 
Coriander 37 Peppermint 46 
p-Cymene 36 Petitgrain 46 
Cypress 36 Pine Needle 33 
Dill Seed 33 Ravensara 46 
Douglas Fir 36 Roman Chamomila 45 
Elemi 50 Rose Absolute 50 
Eucalyptus Lemon 48 Rosemary 61 
Eugenol 60 Rosemary Verbenon 55 
Fennel 43 Rosewood 36 
Frankincense 36 Sage 33 
Geranium Bourbon 36 Sandalwood 39 
Ginger 45 Spearmint 41 
Grapefruit 43 Spruce Needle 62 
Hyssop 41 Tangerine 45 
Jasmine Absolute 51 Thyme Borneal 78 
Juniper Berry 52 Vanilla 53 
Lavender 31 Wintergreen 68 
Lemongrass 31 Ylang Ylang 44 
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Figure 11a.  This Figure Shows the Essential Oils that Exhibited ≤20% Inhibition of 
CYP2C9 Activity.  Those oils include nutmeg, lemongrass, marjoram, pine needle, 
jasmine absolute, hyssop and limonene. 
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Figure 11b.  This Figure Shows the Essential Oils that Exhibited ≤30% Inhibition of 
CYP2C9 Activity.  Those oils include rosewood, frankincense, black pepper, tangerine, 
sage, patchouli, lavender, rose absolute, spearmint, wintergreen, cypress, cedarwood, 
birch, rosemary verbenon, and rosemary. 
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Figure 11c.  This Figure Shows the Essential Oils that Exhibited ≤40% Inhibition of 
CYP2C9 Activity.  Those oils include pennyroyal, ylang ylang, roman chamomile, p-
cymene, fennel, thyme borneal, douglas fir, ravensara, peppermint, eucalyptus lemon, 
mandarin, melissa pure, and anise. 
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Figure 11d.  This Figure Shows the Essential Oils that Exhibited <50% Inhibition of 
CYP2C9 Activity.  Those oils include grapefruit, myrrh, lime, myrtle, spruce needle, 
camphor, dill seed, and sandalwood. 
 
 
 
Of the 60 essential oils tested, there were several different oils that had >50% 
inhibition when compared to an uninhibited reaction.  The essential oils that showed  
inhibition >50% were all spice, bergamot, cardamom, carrot seed, cinnamon leaf, 
citronella, clary sage, clove bud, coriander, elemi, ginger, eugenol, geranium bourbon, 
oregano vulgare, neroli, petitgrain, and vanilla (shown in Figure 12 ). 
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Figure 12.  This Graph Shows the Seventeen Essential Oils that Showed >50% Inhibition 
of CYP2C9 Activity when Compared to an Uninhibited Reaction. 
 
 
 As seen in figure 12, clary sage showed >50% inhibition of CYP2C9 activity.  
Clary sage reduced the activity of CYP2C9 from 100% to 29%.  After the screening 
process determined that these seventeen essential oils showed >50% inhibition, the type 
of inhibition needed to be determined.  This was done by using Michaelis-Menten 
enzyme kinetics. 
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III.B. Enzyme Kinetics Analysis 
 A more precise characterization of the inhibitory effects of the essential oils on 
the activity of CYP2C9 was done via kinetic analysis using the Michaelis-Menten model 
of enzyme kinetics and inhibition.  The kinetic experiments were carried out using 3 
different concentrations of diclofenac ranging from 25 µM to 125 µM in the presence and 
absence of inhibitor in duplicate to ensure reproducibility.  The concentration of oil was 
selected for each experiment was based on the results of the initial screening studies.  A 
concentration was selected where ≥50% inhibition was observed under the standard 
conditions used in the screening process.  Human liver microsomes were incubated with 
one of the seventeen oils examined and diclofenac using difference concentrations of the 
substrate ranging from 25 µM to 125 µM.  The relative activities (determined by 
integrating the peak area for the product 4-hydroxydiclofenac) were plotted against the 
concentration of diclofenac as in a Michaelis-Menten model.  Based on the observation 
that the Vmax for the control experiments and those that had inhibitor present were 
roughly the same, a competitive model of inhibition was used to calculate the Ki for each 
of the seventeen oils examined, in order to obtain a quantitative measure of the inhibition.  
Table 7 shows the Km, Km app, Vmax, Vmax app, and the Ki for each of the seventeen 
essential oils that showed >50% inhibition of CYP2C9 activity 
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Table 7.  This Shows the Michaelis-Menten Calculations for the Seventeen Oils that 
Showed >50% Inhibition of CYP2C9 Activity. Averaged Ki values and error values 
calculated for CYP2C9 inhibition activity of the seventeen oils tested.  The Km, Kmapp, 
Vmax, and Vmax app are included for all of the oils. 
Essential 
Oil 
Ki 
(µg/mL) 
Error 
(µg/mL) 
 
Km 
 
Km app 
 
Vmax 
(µmol/min) 
 
Vmax app 
(µmol/min)
Geranium 
Bourbon 
26 ±0.51 48 114 781 816 
Elemi 4.7 ±2 27 316 516 516 
Ginger 250 ±0.19 27 32 516 516 
Coriander 28 ±0.22 27 63 516 516 
Cinnamon 
Leaf 
28 ±1 88 250 452 367 
Neroli 88 ±0.40 48 73 781 781 
Petitgrain 43 ±0.43 48 154 781 781 
Vanilla 141 ±0.44 48 66 781 781 
Clove Bud 24 ±0.44 27 78 516 516 
Eugenol 34 ±0.42 48 132 781 781 
Cardamom 87 ±0.96 88 129 452 403 
Citronella 26 ±0.62 27 71 516 462 
Oregano 
Vulgare 
24 ±0.40 48 177 781 781 
All Spice 106 ±1.2 88 131 452 357 
Carrot 
Seed 
18 ±1.1 88 146 452 263 
Bergamot 20 ±0.89 88 250 452 452 
Clary Sage 16 ±0.29 27 86 516 516 
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Of the seventeen oils tested using the Michaelis-Menten model, elemi was found 
to be the most potent inhibitor based on its calculated Ki.  To show how the values in 
Table 7 were obtained, sample kinetic plot for each of the seventeen oils are shown in 
Figure 13 through Figure 29.  Figure 13 shows a Michaelis-Menten plot for elemi.  Based 
on the data shown in the Michaelis-Menten plot (Figure 13), a Vmax and a Km were 
calculated in the presences and absence of elemi.  Based on the observation that the 
Vmax was relatively unaffected, the competitive model of inhibition was used to 
calculate a Ki of 4.7 µg/mL for elemi.  The Km was 27 and the Km app was 316.  The ratio 
of Km app to Km was set equal to α and substitute in to equation 3. 
 
Equation 3.  Ratio of Km app to Km for competitive inhibition. 
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Figure 13.  Plot Area vs. Diclofenac (µM) Concentration in the Presence (blue circles) 
and Absence (red triangles) of Elemi.  Reactions contained inhibitor, human liver 
microsomes, a range of substrate concentrations from 25 µM to 125 µM, and NADPH. 
 
 
 
Of the seventeen oils tested, ginger oil was found to be the least potent inhibitor 
based on Michaelis-Menten experiments.  The corresponding data for α of ginger oil is 
included.  Based on the Michaelis-Menten plot (Figure 14), a Vmax, Km were calculated in 
the presence of ginger oil.  The Vmax was relatively unaffected by the presence of the oil 
and thus a competitive model of inhibition was used to calculate a Ki of 250 µg/mL.  This 
is in contradictory to the results of the screening process where >50% inhibition was 
observed which could be due to the citral present in the ginger oil.  Another explanation 
for  the effects of ginger oil not being as potent when compared to the secreting process, 
is that aldehydes that are present in small amounts in essential oils, which can be 
inhibitors of CYP450’s, can form hydrates over time and lose the ability to inhibit 
activity. 
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Figure 14. Plot Area vs. Diclofenac (µM) Concentration in the Presence (blue circles) and 
Absence (red triangles) of Ginger Oil.  Reactions contained inhibitor, human liver 
microsomes, a range of substrate concentrations from 25 µM to 125 µM, and NADPH. 
 
 
 
 The other fifteen essential oil had moderate to low inhibitiory activity.  The oils 
that showed moderate inhibitory activity were geranium bourbon, coriander, cinnamon 
leaf, clove bud, eugenol, citronella, oregano vulgare, carrot seed, bergamot, and clary 
sage.  The value of the Ki for these oils ranged from 16 µg/mL to 34 µg/mL.  Based on 
the Michaelis-Menten plots for these moderate inhibitors (Figure 15-24), a Vmax and Km 
were calculated in the presence and absence of inhibitor.  The Vmax was unaffected by 
the presence of the oil and thus a competitive model of inhibition was used to calculate 
the Ki of the oils.  The oils that showed low inhibitory activity were neroli, petitgrain, 
vanilla, cardamom, and all spice.  The value of the Ki for these oils ranged from 43 
µg/mL to 141 µg/mL.  Based on the Michaelis-Menten plots for these moderate inhibitors 
(Figure 24-28), a Vmax and Km were calculated in the presence and absence of inhibitor.  
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The Vmax was unaffected by the presence of the oil and thus a competitive model of 
inhibition was used to calculate the Ki of the oils. 
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Figure 15. Plot Area vs. Diclofenac (µM) Concentration in the Presence (blue circles) and 
Absence (red triangles) of Geranium Bourbon oil.  Reactions contained inhibitor, human 
liver microsomes, a range of substrate concentrations from 25 µM to 125 µM, and 
NADPH. 
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Figure 16. Plot Area vs. Diclofenac (µM) Concentration in the Presence (blue circles) and 
Absence (red triangles) of Coriander Oil.  Reactions contained inhibitor, human liver 
microsomes, a range of substrate concentrations from 25 µM to 125 µM, and NADPH. 
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Figure 17. Plot Area vs. Diclofenac (µM) Concentration in the Presence (blue circles) and 
Absence (red triangles) of Cinnamon Leaf Oil.  Reactions contained inhibitor, human 
liver microsomes, a range of substrate concentrations from 25 µM to 125 µM, and 
NADPH. 
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Figure 18. Plot Area vs. Diclofenac (µM) Concentration in the Presence (blue circles) and 
Absence (red triangles) of Clove Bud Oil.  Reactions contained inhibitor, human liver 
microsomes, a range of substrate concentrations from 25 µM to 125 µM, and NADPH. 
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Figure 19. Plot Area vs. Diclofenac (µM) Concentration in the Presence (blue circles) and 
Absence (red triangles) of Eugenol Oil.  Reactions contained inhibitor, human liver 
microsomes, a range of substrate concentrations from 25 µM to 125 µM, and NADPH. 
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Figure 20. Plot Area vs. Diclofenac (µM) Concentration in the Presence (blue circles) and 
Absence (red triangles) of Citronella Oil.  Reactions contained inhibitor, human liver 
microsomes, a range of substrate concentrations from 25 µM to 125 µM, and NADPH. 
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Figure 21.  Plot Area vs. Diclofenac (µM) Concentration in the Presence (blue circles) 
and Absence (red triangles) of Oregano Vulgare Oil.  Reactions contained inhibitor, 
human liver microsomes, a range of substrate concentrations from 25 µM to 125 µM, and 
NADPH. 
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Figure 22. Plot Area vs. Diclofenac (µM) Concentration in the Presence (blue circles) and 
Absence (red triangles) of Carrot Seed Oil.  Reactions contained inhibitor, human liver 
microsomes, a range of substrate concentrations from 25 µM to 125 µM, and NADPH. 
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Figure 23. Plot Area vs. Diclofenac (µM) Concentration in the Presence (blue circles) and 
Absence (red triangles) of Bergamot Oil.  Reactions contained inhibitor, human liver 
microsomes, a range of substrate concentrations from 25 µM to 125 µM, and NADPH. 
 
 
 
 
 
 
 
50 
 
Figure 24. Plot Area vs. Diclofenac (µM) Concentration in the Presence (blue circles) and 
Absence (red triangles) of Clary Sage Oil.  Reactions contained inhibitor, human liver 
microsomes, a range of substrate concentrations from 25 µM to 125 µM, and NADPH. 
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Figure 25. Plot Area vs. Diclofenac (µM) Concentration in the Presence (blue circles) and 
Absence (red triangles) of Neroli Oil.  Reactions contained inhibitor, human liver 
microsomes, a range of substrate concentrations from 25 µM to 125 µM, and NADPH. 
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Figure 26. Plot Area vs. Diclofenac (µM) Concentration in the Presence (blue circles) and 
Absence (red triangles) of Petitgrain Oil.  Reactions contained inhibitor, human liver 
microsomes, a range of substrate concentrations from 25 µM to 125 µM, and NADPH. 
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Figure 27. Plot Area vs. Diclofenac (µM) Concentration in the Presence (blue circles) and 
Absence (red triangles) of Vanilla Oil.  Reactions contained inhibitor, human liver 
microsomes, a range of substrate concentrations from 25 µM to 125 µM, and NADPH. 
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Figure 28. Plot Area vs. Diclofenac (µM) Concentration in the Presence (blue circles) and 
Absence (red triangles) of Cardamom Oil.  Reactions contained inhibitor, human liver 
microsomes, a range of substrate concentrations from 25 µM to 125 µM, and NADPH. 
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Figure 29.  Plot Area vs. Diclofenac (µM) Concentration in the Presence (blue circles) 
and Absence (red triangles) of All Spice Oil.  Reactions contained inhibitor, human liver 
microsomes, a range of substrate concentrations from 25 µM to 125 µM, and NADPH.  
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III.C. Reversibility Studies Results 
 
 To determine if the inhibitor was reversible or irreversible, a two stage 
reversibility study was done.  Table 8 shows the results of the reversibility studies. Vial 1 
in this experiment represented reaction conditions which would allow the inhibitors 
present in the essential oils to do damage to the cytochrome P450, if the reaction is 
irreversible then there would be no or a decreased amount of remaining activity toward 
the substrate when the 40 µL is transferred to stage 2, but if it happens to be reversible 
then there would be a full recovery of activity with the substrate in stage 2 to the 
cytochrome P450.  NADPH is added to vial 1 to see if the inhibition of the cytochrome 
P450 is dependent on NADPH.  In vial 2, everything is the same as in vial 1, except that 
no NADPH is present.  Vial 3 represents a control, with microsomes and buffer, when 
transferred to stage 2 the substrate should be able to bind to the cytochrome P450 and 
give full activity which can be compared to vial 1 and vial 2. 
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Table 8.  Results of Reversibility Studies.  Vial 1 corresponds with the reaction that was 
preincubated with the inhibitor and NADPH. Vial 2 corresponds with the reaction that 
was just preincubated with just inhibitor.  Vial 3 corresponds to a control reaction in 
which no inhibitor was added or substrate was added to the preincubation phase. 
Essential Oil Vial 1 Vial 2 Vial 3 
All Spice 85±8 102±12 100±9 
Bergamot 100±8 93±9 100±9 
Cardamom 78±12 80±10 100±10 
Carrot Seed 78±13 76±10 100±7 
Cinnamon Leaf 105±4 106±6 100±3 
Citronella 63±7 74±6 100±6 
Clary Sage 73±5 74±13 100±10 
Clove Bud 106±8 117±8 100±10 
Coriander 89±5 98±6 100±6 
Elemi 91±8 84±9 100±6 
Eugenol 82±10 82±8 100±10 
Geranium Bourbon 110±6 100±6 100±5 
Ginger 104±2 102±2 100±4 
Neroli 81±12 102±10 100±8 
Oregano Vulgare 55±4 61±4 100±6 
Petitgrain 105±2 96±3 100±3 
Vanilla 105±4 96±3 100±4 
 
 
One oil was of particular interest, oregano vulgare oil.  When looking at the 
results of the reversibility study, sixteen of the seventeen essential oils fell within the 
parameters of reversible inhibition.  This can be seen when comparing the activity of vial 
1 and vial 2.  When looking at the results of vial 1 (with vial 3), if a oils is causing 
inhibition there should be a significant decrease in activity and when that is compared to 
vial 3.  A decrease in activity in vial 1 relative to vial 2 signifies that there is a 
mechanism based inactivation of the enzyme even after the incubation phase which 
contains substrate.  This is one type or irreversible inhibition that can occur and it is 
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dependent on enzyme turnover rate.  For example, when looking at oregano oil the 
activity for vial 1, the oil significantly decreased the activity of the enzyme which was 
not able to be restored when substrate was introduced into the system.  This means that 
there is potentially mechanism based inhibition occurring.  When looking at vial 2, the 
same conditions are being looked at except there was no NADPH present in the 
preincubation phase.  The inhibition occurring in this reaction does not require enzyme 
activation.  This can be referred to as direct inactivation rather than mechanism based 
inactivation.  Of the oils tested, oregano vulgare was the only oil that showed 
significantly decreased enzyme activity.  The rate of inactivation was further studied for 
oregano vulgare. 
III.D. Rate of Inactivation Studies 
This study was done to see the rate at which the inhibitor was deactivation the 
enzyme. Like the reversibility studies, there are two phases in which the reaction occurs:  
the preincubation phase (stage 1) and the incubation phase (stage 2).  Figure 30 show the 
graph depicting the rate of inactivation.  The calculated rate of inactivation was 0.78  
min-1.   
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Figure 30.  Rate of Inactivation Assay Plot for Oregano Vulgare.  The time intervals for 
the preincubation solutions was 10, 20, and 30 minutes. 
 
 
 
 This study can be compared to the rate of inactivation of CYP3A4 with the 
component of grapefruit, bergamottin.  Bergamottin is a known inhibitor of CYP3A4 
with a rate of inactivation of 0.3 min-1 (16).  This means that the bergamottin is 
decreasing the activity of the enzymes present in solution at a rate of 0.3 per minute.  In 
the case of this study, oregano oils is destroying the enzyme at a rate of 0.78 min-1 which 
results in a loss of overall activity which was not able to be restored.
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